SiCK2 - Sickness Prior to Chemotherapy in Kids Study 2
Research type
Research Study
Full title
Prevalence of Anticipatory Nausea and Vomiting in Children Undergoing Cytotoxic Chemotherapy for Malignant Disease-The SiCK 2 (Sickness Prior to Chemotherapy) Study.
IRAS ID
232500
Contact name
Lucy Wellings
Contact email
Sponsor organisation
Leeds Teaching Hospital NHS Trust
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
The SiCK 2 (Sickness Prior to Chemotherapy in Kids) study:
Prevalence of anticipatory nausea and vomiting in children undergoing cytotoxic chemotherapy for malignant disease.
Patients undergoing cytotoxic chemotherapy as part of cancer treatment often develop numerous side effects, including nausea and vomiting. Nausea and vomiting symptoms have a significant negative impact on quality of life for children having treatment for cancer. The phenomenon of “anticipatory” nausea and vomiting (i.e. that which develops prior to the administration of chemotherapeutic agents) has also been described. Despite availability of modern anti-emetics, it is estimated to affect around 10% of adults receiving cancer treatment, with nausea more common than vomiting. However, the prevalence of this in children is less well reported.
The study aims to recruit children and young adults under the age of 18 years undergoing chemotherapy as part of their treatment for malignant disease. Patients will be recruited from paediatric oncology centres from the United Kingdom, with the aim to recruit 250 patients. The study will run over 6 weeks to gain optimal recruitment and participants will be asked to complete a questionnaire prior to their chemotherapy treatment. The questionnaire aims to measure the occurrence and severity of anticipatory nausea and vomitingREC name
London - Queen Square Research Ethics Committee
REC reference
18/LO/0598
Date of REC Opinion
24 Apr 2018
REC opinion
Further Information Favourable Opinion